26 results on '"Vieito, Maria"'
Search Results
2. Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.
3. First-in-human study of PM14 in patients with advanced solid tumors.
4. ItRECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy.
5. Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.
6. Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT).
7. Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
8. INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.
9. A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
10. Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
11. Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
12. Frequency of overexpression of HER3 and prognostic consequences in European patients with early gastric cancer.
13. Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.
14. A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.
15. Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.
16. New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
17. EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
18. Use of a new prognostic score as a tool to optimize medical treatment in malignant bowel obstruction.
19. Adjuvant chemoradiotherapy with infusional fluorouracil in high-risk adenocarcinoma of the stomach or gastroesophageal junction.
20. Prognostic factors in stage II colon cancer after radical resection.
21. Low-dose metronomic oral cyclophosphamide plus prednisone for castration resistant prostate cancer (CRPC): A retrospective study.
22. Neoadjuvant chemotherapy followed by chemoradiation in selected locally advanced squamous cervical cancer.
23. Epidemiology, risk factors, and outcomes in malignant bowel obstruction.
24. Metastatic and unresectable biliary tract tumors: A single-center retrospective review.
25. Retrospective study of febrile neutropenia.
26. Molecular characterization of circulating tumor cells in human metastatic colorectal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.